TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study to assess the safety,
tolerability, efficacy, PK, and PD of the chimeric dopamine-somatostatin receptor agonist,
TBR-760, in adult patients with NFPA over 52 weeks.